OTC/PN Member Login
Kremlin on the Schuylkill: McNeil To Gut Contaminated Plant PDF Print E-mail
July 16, 2010 by Donald Riker, PhD   

Article


KremlinIn a hard-to-find, unsigned statement McNeil, not "J&J", issued a Kremlinesque announcement of job lay-offs of 75% of standing headcount and an extended shut-down at its Fort Washington plant lasting into 2011 following its plant contamination and cavalier management.  The fact that this statement was not issued as a corporate press release on its websites confirms more "skulking on the Schuylkill".

 

After months of furtive recalls J&J released an outline of a plan submitted to the FDA to fix the collapse of its quality control systems governing its OTC products.  As predicted by OTC Product News in a series of editorials filed as early as December, 2009 the fixes hint at major organizational changes, process improvement, use of outside experts, and rebuilding of plant & equipment.  J&J will transfer manufacturing to other plants not affected by the outage (which ones are not identified) but still won't be able to build inventory until year end.

One pregnant question unanswered in the press is whether the quality system SOP's, reporting relationships, and systems are truly restricted to one division of the J&J corporate hierarchy.  Quality regulations make little distinction between Rx and OTC products.  Early in this evolving story J&J's medical device division received a stern warning letter related to its sterilization devices failures, for example.  In trying to contain the PR damage of the Tylenol mess no one has seen fit to assure doctors, third-party payers, or patients as to whether the quality systems governing prescription drug handling and manufacture are subsumed by the same broken system.  Does anyone care about the quality of J&J's Rx products?  To paraphrase a Financial Times reporter's recent quizzical metaphor:  "If this is a contagion is it spread by sharing needles?"

 

Don Riker

Donald K. Riker, Ph.D.
Dr. Riker, President & Founder, On Point Advisors, LLC, is a former Associate Director, Personal Healthcare at Procter & Gamble, and the last Vice President of R&D/QA & Chief Scientific Officer at Chattem

Comments


 
-1 # farokh etemadieh 2010-07-16 21:03
very well said. thank you!
Reply | Reply with quote | Quote
 

Add comment


Security code
Refresh

Sign up  for our Email Alerts

 
OTC Product News logo

On Point Advisors, LLC, or its affiliate OTC Product News, provide unbiased opinion on companies, products and events in the OTC industry and receive no financial incentive to promote or influence its opinion of any company or product, and disclose and disclaim any potential conflict of interest herein  (Read full disclaimer)

template cond = default

page class = homepage

option = com_content

view =

Category =

Itemid =